0.3113 USD
-0.24 (-43.3%)
0.289 USD
-0.02 (-7.16%)
ZVSA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. The financial health of ZVSA is average, but there are quite some concerns on its profitability. ZVSA has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year ZVSA has reported negative net income.
- ZVSA had a negative operating cash flow in the past year.
- In the past 5 years ZVSA always reported negative net income.
- ZVSA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- ZVSA has a Return On Assets of -42.14%. This is comparable to the rest of the industry: ZVSA outperforms 55.04% of its industry peers.
- With a Return On Equity value of -108.77%, ZVSA perfoms like the industry average, outperforming 43.70% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.14% | ||
| ROE | -108.77% | ||
| ROIC | N/A |
ROA(3y)-182.17%
ROA(5y)-622.67%
ROE(3y)-364.67%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ZVSA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The number of shares outstanding for ZVSA has been increased compared to 1 year ago.
- ZVSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- ZVSA has an Altman-Z score of -9.49. This is a bad value and indicates that ZVSA is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -9.49, ZVSA is doing worse than 72.12% of the companies in the same industry.
- ZVSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.49 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- ZVSA has a Current Ratio of 0.18. This is a bad value and indicates that ZVSA is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Current ratio of ZVSA (0.18) is worse than 95.86% of its industry peers.
- A Quick Ratio of 0.18 indicates that ZVSA may have some problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 0.18, ZVSA is doing worse than 95.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.18 | ||
| Quick Ratio | 0.18 |
3. Growth
3.1 Past
- ZVSA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.60%, which is quite impressive.
EPS 1Y (TTM)99.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to decrease by -21.81% on average over the next years. This is quite bad
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y93%
EPS Next 2Y33.34%
EPS Next 3Y-38.29%
EPS Next 5Y-21.81%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- ZVSA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year ZVSA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as ZVSA's earnings are expected to decrease with -38.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.34%
EPS Next 3Y-38.29%
5. Dividend
5.1 Amount
- ZVSA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ZYVERSA THERAPEUTICS INC / ZVSA FAQ
Can you provide the ChartMill fundamental rating for ZYVERSA THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 1 / 10 to ZVSA.
Can you provide the valuation status for ZYVERSA THERAPEUTICS INC?
ChartMill assigns a valuation rating of 0 / 10 to ZYVERSA THERAPEUTICS INC (ZVSA). This can be considered as Overvalued.
Can you provide the profitability details for ZYVERSA THERAPEUTICS INC?
ZYVERSA THERAPEUTICS INC (ZVSA) has a profitability rating of 1 / 10.
What is the expected EPS growth for ZYVERSA THERAPEUTICS INC (ZVSA) stock?
The Earnings per Share (EPS) of ZYVERSA THERAPEUTICS INC (ZVSA) is expected to grow by 93% in the next year.